Back to top
more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$135.40 USD

135.40
200,506

+2.75 (2.07%)

Updated Jun 27, 2024 04:00 PM ET

After-Market: $135.56 +0.16 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ASND

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Ascendis Pharma A/S [ASND/]

Reports for Purchase

Showing records 281 - 300 ( 303 total )

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 281

04/13/2017

Daily Note

Pages: 8

Corporate Update: Remaining 2017 Catalysts Include Pipeline Progress, Potential for a TransCon Deal and Long-Acting hGH Competition

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 282

04/04/2017

Daily Note

Pages: 46

April and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 283

04/03/2017

Daily Note

Pages: 6

ENDO: Eight Pipeline Presentations Provide Plenty of Exposure for Endocrinologists; Reiterate OUTPERFORM and $34 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 284

03/31/2017

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 285

03/24/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences: Upcoming Events for the Week of March 27

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 286

03/24/2017

Company Report

Pages: 7

Q4/FY16 Financials; Pipeline Progress on Multiple Fronts; Reiterate OUTPERFORM and Raising PT to $34 for Time Value

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 287

03/23/2017

Company Report

Pages: 7

Q4/FY16 Financials; Pipeline Progress on Multiple Fronts; Reiterate OUTPERFORM and Raising PT to $34 for Time Value

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 288

03/17/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of March 20

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 289

03/08/2017

Daily Note

Pages: 42

March and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 290

02/24/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 291

02/23/2017

Daily Note

Pages: 7

Pediatric and Adult GHD Publications Validate TC-hGH Phase 2 Results in Our View; Reiterate OUTPERFORM and $31 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 292

02/06/2017

Daily Note

Pages: 45

February and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 293

01/03/2017

Daily Note

Pages: 40

January and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 294

12/16/2016

Company Report

Pages: 20

Key Opinion Leader Views TC-hGH as a Top Candidate for Long-Acting hGH; Reiterate OUTPERFORM and $31 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 295

12/05/2016

Daily Note

Pages: 39

December and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 296

12/01/2016

Company Report

Pages: 7

Q3 Update; Pivotal Trial for TransCon hGH on Track with Enrollment Initiated; Reiterate OUTPERFORM and $31 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 297

12/01/2016

Company Report

Pages: 7

Q3 Update; Pivotal Trial for TransCon hGH on Track with Enrollment Initiated; Reiterate OUTPERFORM and $31 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 298

11/18/2016

Industry Report

Pages: 7

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 299

11/07/2016

Daily Note

Pages: 44

November and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 300

10/20/2016

Company Report

Pages: 7

Financing Covers Pivotal Data Readout for TransCon hGH; Reiterate OUTPERFORM but Reducing Price Target to $31 (from $34) for Dilution

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party